Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Deloitte
Farmers Insurance
Julphar
Covington
US Department of Justice
Colorcon
Citi
Cipla

Generated: June 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,245,819

« Back to Dashboard

Which drugs does patent 6,245,819 protect, and when does it expire?

Patent 6,245,819 protects OSPHENA and is included in one NDA.

This patent has thirty-eight patent family members in twenty-eight countries.
Summary for Patent: 6,245,819
Title: Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
Abstract:This invention concerns a method for the treatment of vaginal dryness or sexual dysfunction in women during or after the menopause, said method comprising administering to the woman an effective amount of the compound (deaminohydroxy)toremifene or a pharmaceutically acceptable salt or ester thereof, or a metabolite thereof.
Inventor(s): Halonen; Kaija (Rusko, FI), Kangas; Lauri (Raisio, FI), DeGregorio; Michael W. (Granite Bay, CA)
Assignee: Hormos Medical Oy, Ltd. (FI) Tess Diagnostics and Pharmaceuticals, Inc. (Granite Bay, CA)
Application Number:09/625,199
Patent Claim Types:
see list of patent claims
Use; Compound; Delivery;

Drugs Protected by US Patent 6,245,819

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Duchesnay OSPHENA ospemifene TABLET;ORAL 203505-001 Feb 26, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,245,819

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,984,665 Methods for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in women ➤ Try a Free Trial
9,566,252 Method for the alleviation of dyspareunia in women ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 6,245,819

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovakia 287096 ➤ Try a Free Trial
Slovakia 16072002 ➤ Try a Free Trial
Slovenia 1305014 ➤ Try a Free Trial
Russian Federation 2268035 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
US Army
McKesson
Boehringer Ingelheim
Moodys
Covington
McKinsey
Chubb
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.